These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24919168)

  • 1. The early longitudinal course of cognitive deficits in schizophrenia.
    Nuechterlein KH; Ventura J; Subotnik KL; Bartzokis G
    J Clin Psychiatry; 2014; 75 Suppl 2(0 2):25-9. PubMed ID: 24919168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness.
    Keefe RS
    J Clin Psychiatry; 2014; 75 Suppl 2():8-13. PubMed ID: 24919165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact on cognition of the use of antipsychotics.
    Sharma T
    Curr Med Res Opin; 2002; 18 Suppl 3():s13-7. PubMed ID: 12418607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can genetics inform the management of cognitive deficits in schizophrenia?
    Vyas NS; Shamsi SA; Malhotra AK; Aitchison KJ; Kumari V
    J Psychopharmacol; 2012 Mar; 26(3):334-48. PubMed ID: 22328662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment].
    Lecardeur L; Meunier-Cussac S; Dollfus S
    Encephale; 2013 May; 39 Suppl 1():S64-71. PubMed ID: 23528322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
    JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive deficits as treatment targets in schizophrenia.
    Gold JM
    Schizophr Res; 2004 Dec; 72(1):21-8. PubMed ID: 15531404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment.
    Flashman LA; Green MF
    Psychiatr Clin North Am; 2004 Mar; 27(1):1-18, vii. PubMed ID: 15062627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature.
    Bozikas VP; Andreou C
    Aust N Z J Psychiatry; 2011 Feb; 45(2):93-108. PubMed ID: 21320033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive functioning in schizophrenia and during the early phases of psychosis: targeting cognitive remediation interventions.
    Zaytseva Y; Korsakova N; Agius M; Gurovich I
    Biomed Res Int; 2013; 2013():819587. PubMed ID: 24089689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [First-episode psychosis, cognitive difficulties and remediation].
    Vidailhet P
    Encephale; 2013 Sep; 39 Suppl 2():S83-92. PubMed ID: 24084427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder.
    Lewandowski KE; Cohen BM; Ongur D
    Psychol Med; 2011 Feb; 41(2):225-41. PubMed ID: 20836900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive course in first-episode psychosis and clinical correlates: A 4 year longitudinal study using the MATRICS Consensus Cognitive Battery.
    Kenney J; Anderson-Schmidt H; Scanlon C; Arndt S; Scherz E; McInerney S; McFarland J; Byrne F; Ahmed M; Donohoe G; Hallahan B; McDonald C; Cannon DM
    Schizophr Res; 2015 Dec; 169(1-3):101-108. PubMed ID: 26416442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication.
    Campagna EJ; Muser E; Parks J; Morrato EH
    J Manag Care Spec Pharm; 2014 Jul; 20(7):756-66. PubMed ID: 24967528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Age at Onset and Longitudinal Course of Prefrontal Function in Youth With Schizophrenia.
    Niendam TA; Ray KL; Iosif AM; Lesh TA; Ashby SR; Patel PK; Smucny J; Ferrer E; Solomon M; Ragland JD; Carter CS
    JAMA Psychiatry; 2018 Dec; 75(12):1252-1260. PubMed ID: 30285056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do clinical characteristics predict the cognitive course in early-onset schizophrenia-spectrum disorders?
    Teigset CM; Mohn C; Brunborg C; Juuhl-Langseth M; Holmén A; Rund BR
    J Child Psychol Psychiatry; 2018 Sep; 59(9):1012-1023. PubMed ID: 29573345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What do we know about neuropsychological aspects of schizophrenia?
    Palmer BW; Dawes SE; Heaton RK
    Neuropsychol Rev; 2009 Sep; 19(3):365-84. PubMed ID: 19639412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of longitudinal studies of cognitive functions in schizophrenia patients.
    Rund BR
    Schizophr Bull; 1998; 24(3):425-35. PubMed ID: 9718634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.